JP2009519931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519931A5 JP2009519931A5 JP2008545643A JP2008545643A JP2009519931A5 JP 2009519931 A5 JP2009519931 A5 JP 2009519931A5 JP 2008545643 A JP2008545643 A JP 2008545643A JP 2008545643 A JP2008545643 A JP 2008545643A JP 2009519931 A5 JP2009519931 A5 JP 2009519931A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- group
- flt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 31
- 108091007172 antigens Proteins 0.000 claims 31
- 102000038129 antigens Human genes 0.000 claims 31
- -1 Ba 733 Proteins 0.000 claims 27
- 102000004965 antibodies Human genes 0.000 claims 24
- 108090001123 antibodies Proteins 0.000 claims 24
- 102000004851 Immunoglobulin G Human genes 0.000 claims 13
- 230000027455 binding Effects 0.000 claims 13
- 101710043956 CEACAM5 Proteins 0.000 claims 12
- 102100011842 CEACAM5 Human genes 0.000 claims 12
- 101710043948 CEACAM7 Proteins 0.000 claims 10
- 101700004495 PSG2 Proteins 0.000 claims 10
- 101700020617 CD22 Proteins 0.000 claims 9
- 102100000189 CD22 Human genes 0.000 claims 9
- 102100013180 KDR Human genes 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 102100004099 CD74 Human genes 0.000 claims 8
- 101710007476 CD74 Proteins 0.000 claims 8
- 102100010912 EPCAM Human genes 0.000 claims 8
- 101710030888 KDR Proteins 0.000 claims 8
- 102100000165 MS4A1 Human genes 0.000 claims 8
- 101710010909 MS4A1 Proteins 0.000 claims 8
- 210000004027 cells Anatomy 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 108060002563 EPCAM Proteins 0.000 claims 6
- 101710030892 FLT1 Proteins 0.000 claims 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 6
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 6
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 6
- 230000001575 pathological Effects 0.000 claims 6
- 101700010580 FLO11 Proteins 0.000 claims 5
- 102100006037 MUC1 Human genes 0.000 claims 5
- 101700052761 MUC1 Proteins 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 claims 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 4
- 101710010587 CASP13 Proteins 0.000 claims 4
- 102100005826 CD19 Human genes 0.000 claims 4
- 101700087100 CD19 Proteins 0.000 claims 4
- 102100013082 CD1A Human genes 0.000 claims 4
- 101700015984 CD1A Proteins 0.000 claims 4
- 102100016493 CD33 Human genes 0.000 claims 4
- 101700017647 CD33 Proteins 0.000 claims 4
- 102100011839 CEACAM6 Human genes 0.000 claims 4
- 101710043949 CEACAM6 Proteins 0.000 claims 4
- 102100009705 ENG Human genes 0.000 claims 4
- 102100016662 ERBB2 Human genes 0.000 claims 4
- 101700025368 ERBB2 Proteins 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 102100015541 FCGR3A Human genes 0.000 claims 4
- 101710044656 FCGR3A Proteins 0.000 claims 4
- 101710044657 FCGR3B Proteins 0.000 claims 4
- 102100008658 FN1 Human genes 0.000 claims 4
- 102100008453 FOLH1 Human genes 0.000 claims 4
- 101700036477 FOLH1 Proteins 0.000 claims 4
- 108010067306 Fibronectins Proteins 0.000 claims 4
- 102100014497 GOLPH3 Human genes 0.000 claims 4
- 101710008339 GOLPH3 Proteins 0.000 claims 4
- 101700042506 HIRUD Proteins 0.000 claims 4
- 229940006607 Hirudin Drugs 0.000 claims 4
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 claims 4
- 102100014263 IGF1R Human genes 0.000 claims 4
- 101700025802 IGF1R Proteins 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 108090001007 Interleukin-8 Proteins 0.000 claims 4
- 101700062818 NP Proteins 0.000 claims 4
- 101710043203 P23p89 Proteins 0.000 claims 4
- 101700008337 PSMA Proteins 0.000 claims 4
- 101710037934 QRSL1 Proteins 0.000 claims 4
- 229960005202 Streptokinase Drugs 0.000 claims 4
- 108010023197 Streptokinase Proteins 0.000 claims 4
- 101710040533 TNFRSF8 Proteins 0.000 claims 4
- 102100009538 TNFRSF8 Human genes 0.000 claims 4
- 229960005356 Urokinase Drugs 0.000 claims 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 4
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000037320 fibronectin Effects 0.000 claims 4
- 101710034616 gVIII-1 Proteins 0.000 claims 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 101700045377 mvp1 Proteins 0.000 claims 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 4
- 102100001537 CA9 Human genes 0.000 claims 3
- 101710040946 CA9 Proteins 0.000 claims 3
- 210000001072 Colon Anatomy 0.000 claims 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 3
- 102100006815 IL2RA Human genes 0.000 claims 3
- 101700082799 IL2RA Proteins 0.000 claims 3
- 101700015336 ISG20 Proteins 0.000 claims 3
- 101700010570 MUC17 Proteins 0.000 claims 3
- 102100013951 MUC2 Human genes 0.000 claims 3
- 101700036633 MUC2 Proteins 0.000 claims 3
- 102100013952 MUC3A Human genes 0.000 claims 3
- 101700075415 MUC3A Proteins 0.000 claims 3
- 102100013929 MUC4 Human genes 0.000 claims 3
- 101700032853 MUC4 Proteins 0.000 claims 3
- 101710005665 NECTIN1 Proteins 0.000 claims 3
- 102100019072 NECTIN1 Human genes 0.000 claims 3
- 101700044827 RNMT Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 102000005936 beta-Galactosidase Human genes 0.000 claims 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- HQESMQVYRAJTEA-UHFFFAOYSA-N 4-(carboxymethylamino)-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NCC(O)=O HQESMQVYRAJTEA-UHFFFAOYSA-N 0.000 claims 2
- 102000013563 Acid Phosphatase Human genes 0.000 claims 2
- 108010051457 Acid Phosphatase Proteins 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims 2
- 108010008629 CA-125 Antigen Proteins 0.000 claims 2
- 102100003268 CD14 Human genes 0.000 claims 2
- 101700027514 CD14 Proteins 0.000 claims 2
- 101700085585 CD1B Proteins 0.000 claims 2
- 101700019673 CD1C Proteins 0.000 claims 2
- 101700070268 CD1D Proteins 0.000 claims 2
- 102100019289 CD2 Human genes 0.000 claims 2
- 101700024689 CD2 Proteins 0.000 claims 2
- 102100003279 CD38 Human genes 0.000 claims 2
- 101700044948 CD38 Proteins 0.000 claims 2
- 101710040446 CD40 Proteins 0.000 claims 2
- 102100013137 CD40 Human genes 0.000 claims 2
- 101710003804 CD40LG Proteins 0.000 claims 2
- 102100005828 CD5 Human genes 0.000 claims 2
- 101700066525 CD5 Proteins 0.000 claims 2
- 102100019451 CD80 Human genes 0.000 claims 2
- 101700080477 CD80 Proteins 0.000 claims 2
- 102100009368 CR2 Human genes 0.000 claims 2
- 101700020447 CR2 Proteins 0.000 claims 2
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims 2
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims 2
- 108010036395 Endoglin Proteins 0.000 claims 2
- 229940088598 Enzyme Drugs 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108060003023 F Proteins 0.000 claims 2
- 102100014610 FCAR Human genes 0.000 claims 2
- 101700041688 FCAR Proteins 0.000 claims 2
- 101700053597 FCER2 Proteins 0.000 claims 2
- 102100014608 FCER2 Human genes 0.000 claims 2
- 101710003440 FCGR1A Proteins 0.000 claims 2
- 102100015540 FCGR1A Human genes 0.000 claims 2
- 101710009074 FLT3 Proteins 0.000 claims 2
- 102100019327 FUT4 Human genes 0.000 claims 2
- 101700004786 FUT4 Proteins 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102000006815 Folate receptors Human genes 0.000 claims 2
- 108020005243 Folate receptors Proteins 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- 101710044247 ITGA2B Proteins 0.000 claims 2
- 102100019332 ITGA2B Human genes 0.000 claims 2
- 102100001475 ITGB2 Human genes 0.000 claims 2
- 108090001124 Immunoglobulin E Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000013691 Interleukin-17 Human genes 0.000 claims 2
- 108050003558 Interleukin-17 family Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 101700058542 KLK3 Proteins 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 102100012644 MIF Human genes 0.000 claims 2
- 108060004872 MIF Proteins 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- 102100002997 NPEPPS Human genes 0.000 claims 2
- 101710027788 NPEPPS Proteins 0.000 claims 2
- 229920000272 Oligonucleotide Polymers 0.000 claims 2
- 102100012897 PGF Human genes 0.000 claims 2
- 101710014083 PGF Proteins 0.000 claims 2
- 101710025567 PSAT1 Proteins 0.000 claims 2
- 101700059076 PTPRC Proteins 0.000 claims 2
- 102100005499 PTPRC Human genes 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 101700013615 RFS5 Proteins 0.000 claims 2
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 2
- 101710023234 Segment 5 Proteins 0.000 claims 2
- 229940014598 TAC Drugs 0.000 claims 2
- 102100018484 TACSTD2 Human genes 0.000 claims 2
- 101710024898 TACSTD2 Proteins 0.000 claims 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 2
- 102100019730 TP53 Human genes 0.000 claims 2
- 101710026335 TP53 Proteins 0.000 claims 2
- 102000007000 Tenascin Human genes 0.000 claims 2
- 108010008125 Tenascin Proteins 0.000 claims 2
- 231100000765 Toxin Toxicity 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 206010054094 Tumour necrosis Diseases 0.000 claims 2
- 102100015249 VEGFA Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 101700059128 bre-3 Proteins 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 101700062463 htr1 Proteins 0.000 claims 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 102000003735 mesothelin Human genes 0.000 claims 2
- 108090000015 mesothelin Proteins 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrugs Drugs 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 108020003112 toxins Proteins 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 108010007562 Adalimumab Proteins 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 235000011330 Armoracia rusticana Nutrition 0.000 claims 1
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102000004040 Capsid Proteins Human genes 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 102000002464 Galactosidases Human genes 0.000 claims 1
- 108010093031 Galactosidases Proteins 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 108010053490 Infliximab Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 108010029597 Omalizumab Proteins 0.000 claims 1
- 229960000470 Omalizumab Drugs 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 108020005203 Oxidases Proteins 0.000 claims 1
- 108010019613 Palivizumab Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic Effects 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 230000000890 antigenic Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 108010050895 clivatuzumab Proteins 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 201000010870 diseases of metabolism Diseases 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000003344 immunostimulant Effects 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 108020004084 membrane receptors Proteins 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 102000025475 oncoproteins Human genes 0.000 claims 1
- 108091008124 oncoproteins Proteins 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 230000005298 paramagnetic Effects 0.000 claims 1
- 244000045947 parasites Species 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Claims (32)
- 2個のAD2(配列番号4)部分に結合したIgG抗体と、各断片がDDD2(配列番号2)部分に結合した同一の又は異なるIgGの4本の抗体断片とを含み、前記AD2部分が前記DDD2部分に結合している、6量体の安定係留構造体。
- 前記AD2部分が、前記DDD2部分にジスルフィド結合により共有結合している、請求項1記載の構造体。
- 前記構造体が、6本のFab断片と1本のFc断片を含む、請求項1記載の構造体。
- 前記構造体が、1つのIgG抗体と4本のFv抗体断片を含む、請求項1記載の構造体。
- 前記抗体断片のそれぞれが、同一の抗原エピトープに結合する、請求項1記載の構造体。
- 前記抗体断片のうち2本の断片が第1の抗原エピトープに結合し、そして前記抗体断片のうち4本の断片が第2の抗原エピトープに結合する、請求項1記載の構造体。
- 前記抗体又は抗体断片が、ヒト抗体、ヒト化抗体若しくはキメラ抗体、又はこれらの抗体断片である、請求項1記載の構造体。
- 前記抗体断片が、hMN-14、L19、hA20、hLL2、hL243、hCC49、7E3、hLL1、hPAM4、hRS7、rH1、L49、抗CD 14、抗CD111、アダリムマブ、インフリキシマブ、オマリズマブ、パリビズマブ及びhMN-15の断片から成る群から選択される、請求項1記載の構造体。
- 前記IgG抗体及び/又は抗体断片が、炭酸脱水酵素IX、α-フェトプロテイン、A3、A33抗体の特異的抗原、Ba 733、BrE3抗原、CA125、CD1、CD1a、CD3、CD5、CD15、CD16、CD19、CD20、CD21、CD22、CD23、CD25、CD30、CD33、CD38、CD45、CD74、CD79a、CD80、CD138、大腸特異的抗原-p(colon-specific antigen-p)(CSAp)、CEA(CEACAM5)、CEACAM6、CSAp、EGFR、EGP-1、EGP-2、Ep-CAM、Flt-1、Flt-3、葉酸レセプター、HLA-DR、ヒト絨毛性ゴナドトロピン(HCG)及びそのサブユニット、HER2/neu、低酸素誘導因子(HIF-1)、Ia、IL-2、IL-6、IL-8、インシュリン成長因子-1(IGF-1)、KC4抗原、KS-1抗原、KS1-4、Le-Y、マクロファージ遊走阻止因子(MIF)、MAGE、MUC1、MUC2、MUC3、MUC4、NCA66、NCA95、NCA90、PAM-4抗体の特異的抗原、胎盤成長因子、p53、前立腺酸性フォスファターゼ、PSA、PSMA、RS5、S1OO、TAC、TAG-72、テネイシン、TRAILレセプター、Tn抗原、トムソン-フリーデンライヒ抗原、腫瘍壊死抗原、VEGF、ED-Bフィブロネクチン、17-1A抗原、脈管形成マーカー、癌遺伝子マーカー又は癌遺伝子産物から成る群から選択される抗原に結合する、請求項1記載の構造体。
- 前記構造体に、共有結合若しくは非共有結合により結合した1又は2個以上のエフェクター又は担体を更に含む、請求項1記載の構造体。
- 前記エフェクターが、診断剤、治療剤、化学療法剤、放射線同位体、造影剤(imaging agent)、抗脈管形成剤、サイトカイン、ケモカイン、成長因子、薬物、プロドラッグ、酵素、結合分子、細胞表面レセプターに対するリガンド、キレート剤、免疫調節剤、オリゴヌクレオチド、ホルモン、光検出性標識、色素、ペプチド、毒素、造影剤(contrast agent)、常磁性標識、超音波標識、アポトーシス促進剤、リポソーム、ナノ粒子又はこれらの組み合わせ、である、請求項10記載の構造体。
- 前記IgG抗体及び前記抗体断片が、標的の分子、複合体、凝集体、細胞、抗原又は組織に対する結合親和力を有する、請求項1記載の構造体。
- 前記IgG抗体が、標的の分子、複合体、凝集体、細胞、抗原又は組織に対する結合親和力を有し、そして少なくとも1つの抗体断片が、ハプテンに対する結合部位を有する、請求項1記載の構造体。
- 前記IgG抗体が、細胞表面レセプター、アルカリホスファターゼ、ホースラディッシュロキシダーゼ、β-ガラクトシダーゼ、tpA、ストレプトキナーゼ、ヒルジン、ウロキナーゼ、CA19-9、CEA、CEACAM6、CD19、CD20、CD22、CD30、CD33、CD40、CD74、ED-Bフィブロネクチン、EGFR、GD2、G250抗原、HER2/neu、hTR、HLAクラスII、HMW/MAA、HN/NDV、IGF1R、IL-2R/Tac、IL-17、MUC1、PSMA、M13コートタンパク質、GpIIb/IIIa、CD74、EGP-1、CD25/Tac、LeY、メソセリン(mesothelin)、Erb-B2、Erb-B3、EpCAM、GP240、GPIIb/IIIa、p97、CD3、IL-4R、IL-4、IL-13、VEGFR-2、CD14、CD111/ネクチン-1、葉酸レセプターα、gp120、IL-6、IL-5、IL-8、CD154、IgE、LFA-1、β-トリプターゼ、CD105/エンドグリン(endoglin)、TNFα、RSV Fタンパク質、CEAのA1B1、CEAのNドメイン、PfMSP-1、TAG-72、MUC1、MUC2、MUC3、MUC4、VEFGR1/Flt-1、VEGFR2/KDR又はVEGRF3/Flt-4、に対する結合親和力を有する、請求項13記載の構造体。
- 少なくとも1つの抗体断片が、IL-17、ヒスタミンスクシニルグリシン(HSG)、インジウム-DTPA、CD22、CD20、EGFR、IGF1R、VEFGR1/Flt-1、VEGFR2/KDR、VEGRF3/Flt-4、CD3、CD16、CD64、CD89、CD2、アデノウィルスファイバーノブ、M13コートタンパク質、GpIIb/IIIa、アルカリホスファターゼ、ホースラディッシュペロキシダーゼ、β-ガラクトシダーゼ、tpA、ストレプトキナーゼ、ヒルジン又はウロキナーゼ、に対する結合親和力を有する、請求項14記載の構造体。
- 前記IgG抗体が、CEA、ED-Bフィブロネクチン、CD20、CD22、CD19、EGFR、IGF1R、VEFGR1/Flt-1、VEGFR2/KDR、VEGRF3/Flt-4、HER2/neu、CD30、CD33、PfMSP-1、HN/NDV、EpCAM/17-1A、hTR、IL-2R/Tac、CA19-9、MUC1、HLAクラスII、GD2、G250、TAG-72、PSMA、CEACAM6、HMWMAA、CD40、M13コートタンパク質及びGPIIb/IIIaから成る群から選択される細胞表面抗原に対する結合親和力を有し、そして少なくとも1つの抗体断片が、ヒスタミンスクシニルグリシン(HSG)及びインジウム-DTPAから成る群から選択されるハプテン、又はCD22、CD20、EGFR、IGF1R、VEFGR1 /Flt-1、VEGFR2/KDR、VEGRF3/Flt-4、CD3、CD16、CD64、CD89、CD2及びアデノウィルスファイバーノブから成る群から選択される細胞表面抗原のいずれかに対する結合親和力を有する、請求項13記載の構造体。
- 前記IgG抗体が、M13コートタンパク質及びGpIIb/IIIaから成る群から選択される細胞表面抗原、又はアルカリホスファターゼ、ホースラディッシュペロキシダーゼ、β-ガラクトシダーゼ、tpA、ストレプトキナーゼ、ヒルジン及びウロキナーゼから成る群から選択される生体分子のいずれかに対する結合親和力を有し、そして少なくとも1つの抗体断片が、M13コートタンパク質及びGpIIb/IIIaから成る群から選択される細胞表面抗原、又はアルカリホスファターゼ、ホースラディッシュペロキシダーゼ、β-ガラクトシダーゼ、tpA、ストレプトキナーゼ、ヒルジン及びウロキナーゼから成る群から選択される生体分子のいずれかに対する結合親和力を有する、請求項1記載の構造体。
- 前記IgG抗体及び前記抗体断片が、同一の抗原に結合し、前記抗原が、CD14、CD111/ネクチン-1、葉酸レセプターα、gp120、IL-6、IL-5、IL-8、CD154、IgE、LFA-1、β-トリプターゼ、CD105/エンドグリン(endoglin)、GpIIb/IIIa、TNFα、RSV F-タンパク質、CEAのA1B1及びCEAのNドメインから成る群から選択される、請求項1記載の構造体。
- 前記IgG抗体及び前記抗体断片が、CD20/CD22; CD20/CD74; CD20/HLA-DR; CD22/CD74; CD22/HLA-DR; CD74/HLA-DR; CD74/CEA又はHLA-DR/CEAの抗原の組合せに結合する、請求項5記載の構造体。
- 疾病を伴う又は病的状態にある対象を治療する製剤の製造における請求項1乃至19のいずれか1項に記載の6量体の安定係留構造体の使用において、前記構造体が前記疾病又は病的状態に治療的効果を有する、使用。
- 前記疾病又は病的状態が癌または自己免疫疾患である、請求項20に記載の使用。
- 前記疾病又は病的状態が癌であり、前記IgG抗体及び/又は抗体断片が、炭酸脱水酵素IX、α-フェトプロテイン、A3、A33抗体の特異的抗原、Ba 733、BrE3抗原、CA125、CD1、CD1a、CD3、CD5、CD15、CD16、CD19、CD20、CD21、CD22、CD23、CD25、CD30、CD33、CD38、CD45、CD74、CD79a、CD80、CD138、大腸特異的抗原-p(colon-specific antigen-p)(CSAp)、CEA(CEACAM5)、CEACAM6、EGFR、EGP-1、EGP-2、Ep-CAM、Flt-1、Flt-3、葉酸レセプター、G250抗原、HLA-DR、ヒト絨毛性ゴナドトロピン(HCG)及びそのサブユニット、HER2/neu、低酸素誘導因子(HIF-1)、Ia、IL-2、IL-6、IL-8、インシュリン成長因子-1(IGF-1)、KC4抗原、KS-1抗原、KS1-4、Le-Y、マクロファージ遊走阻止因子(MIF)、MAGE、MUC1、MUC2、MUC3、MUC4、NCA66、NCA95、NCA90、PAM-4抗体の特異的抗原、胎盤成長因子、p53、前立腺酸性フォスファターゼ、PSA、PSMA、RS5、S1OO、TAC、TAG-72、テネイシン、TRAILレセプター、Tn抗原、トムソン-フリーデンライヒ抗原、腫瘍壊死抗原、VEGF、ED-Bフィブロネクチン、17-1A抗原、脈管形成マーカー、癌遺伝子マーカー又は癌遺伝子産物から成る群から選択される腫瘍関連抗原に対する結合親和力を有する、請求項21に記載の使用。
- 一又はそれ以上の抗癌治療の使用と組み合わせた、請求項22に記載の使用。
- 前記治療が、化学療法剤、サイトカイン、放射線療法、免疫療法、放射線免疫療法、局所温熱療法、レーザ照射、抗脈管形成、または外科的切除を含む、請求項23に記載の使用。
- 前記抗体断片の少なくとも1つが、ハプテンに対する結合親和力を有する、請求項22に記載の使用。
- 前記対象へ投与するための前記ハプテンの使用を含む、請求項25に記載の使用。
- 前記ハプテンが、抗脈管形成剤、化学療法剤、サイトカイン、薬物、プロドラッグ、毒素、酵素、オリゴヌクレオチド、放射線同位体、免疫刺激剤、抗生物質、抗ウイルス剤、抗真菌剤、ホルモン、結合分子、脂質、ポリマ、ミセル、リポソーム、ナノ粒子、またはこれらの組み合わせからなる群から選択された薬剤に結合する、請求項26に記載の使用。
- 前記疾病又は病的状態が、真菌、ウイルス、バクテリア、又はパラサイトによって生じる、請求項20に記載の使用。
- 前記疾病又は病的状態が、自己免疫疾患である、請求項20に記載の使用。
- 前記構造体が、IgG抗体と、抗CD74×抗CD20、抗CD74×抗CD22、抗CD22×抗CD20、抗CD20×抗HLA−DR、抗CD19×抗CD20、抗CD20×抗CD80、抗CD2×抗CD25、抗CD8×抗CD25、抗CD2×抗CD147、抗CEACAM54×抗CD3、抗CEACAM6×抗CD3、抗EGFR×抗CD3、抗HER2/neu×抗CD3、抗CD20×抗CD3、抗CD74×抗CD3、及び、抗CD22×抗CD3、からなる群から選択された抗体断片の組み合わせを含む、請求項20に記載の使用。
- 前記疾病又は病的状態が、神経変性症、アルツハイマー病、代謝疾患、心疾患、アテローム性動脈硬化、又は、臓器移植拒否反応である、請求項20に記載の使用。
- 前記癌が、上皮癌、間葉性癌、血液癌、神経癌、上皮性悪性腫瘍、黒色腫、非上皮性悪性腫瘍、神経芽細胞腫、白血病、リンパ腫、神経膠腫及び骨髄腫からなる群から選択される、請求項22に記載の使用。
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75119605P | 2005-12-16 | 2005-12-16 | |
US60/751,196 | 2005-12-16 | ||
US78233206P | 2006-03-14 | 2006-03-14 | |
US60/782,332 | 2006-03-14 | ||
USPCT/US2006/010762 | 2006-03-24 | ||
US11/389,358 | 2006-03-24 | ||
PCT/US2006/010762 WO2006107617A2 (en) | 2005-04-06 | 2006-03-24 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US11/389,358 US7550143B2 (en) | 2005-04-06 | 2006-03-24 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US11/391,584 US7521056B2 (en) | 2005-04-06 | 2006-03-28 | Stably tethered structures of defined compositions with multiple functions or binding specificities |
US11/391,584 | 2006-03-28 | ||
PCT/US2006/012084 WO2006107786A2 (en) | 2005-04-06 | 2006-03-29 | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
USPCT/US2006/012084 | 2006-03-29 | ||
US11/478,021 US7534866B2 (en) | 2005-10-19 | 2006-06-29 | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
USPCT/US2006/025499 | 2006-06-29 | ||
PCT/US2006/025499 WO2007046893A2 (en) | 2005-10-19 | 2006-06-29 | Methods for generating bioactive assemblies and uses thereof |
US11/478,021 | 2006-06-29 | ||
US86453006P | 2006-11-06 | 2006-11-06 | |
US60/864,530 | 2006-11-06 | ||
PCT/US2006/046367 WO2007075270A2 (en) | 2005-12-16 | 2006-12-05 | Multivalent immunoglobulin-based bioactive assemblies |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009519931A JP2009519931A (ja) | 2009-05-21 |
JP2009519931A5 true JP2009519931A5 (ja) | 2010-01-28 |
JP5090366B2 JP5090366B2 (ja) | 2012-12-05 |
Family
ID=48922352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008545643A Active JP5090366B2 (ja) | 2005-12-16 | 2006-12-05 | 多価イムノグロブリン系生物活性アセンブリー |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1959993B1 (ja) |
JP (1) | JP5090366B2 (ja) |
KR (1) | KR101410521B1 (ja) |
CN (3) | CN101374546B (ja) |
AU (1) | AU2006330051B2 (ja) |
CA (1) | CA2633486C (ja) |
HK (1) | HK1117761A1 (ja) |
SG (1) | SG153825A1 (ja) |
WO (1) | WO2007075270A2 (ja) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US8658773B2 (en) * | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US8034352B2 (en) | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
WO2007046893A2 (en) * | 2005-10-19 | 2007-04-26 | Ibc Pharmaceuticals, Inc. | Methods for generating bioactive assemblies and uses thereof |
US8003111B2 (en) | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
US8562988B2 (en) | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
US8491914B2 (en) | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
US7901680B2 (en) | 2005-10-19 | 2011-03-08 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
US8158129B2 (en) | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
EP1874824A4 (en) | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US9931413B2 (en) | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
AU2011292178B8 (en) * | 2006-12-05 | 2016-01-21 | Ibc Pharmaceuticals, Inc. | Compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. the therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
EP2237797A4 (en) | 2008-01-03 | 2012-11-07 | Scripps Research Inst | TARGETING ANTIBODIES BY MODULAR RECOGNITION DOMAIN |
US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
CN102119175A (zh) * | 2008-04-10 | 2011-07-06 | Ibc药品公司 | 采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法 |
WO2010028796A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
US8535477B2 (en) | 2009-02-21 | 2013-09-17 | Sofradim Production | Medical devices incorporating functional adhesives |
US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
ES2557914T3 (es) | 2009-03-24 | 2016-01-29 | Biocept, Inc. | Dispositivos y métodos de captura y análisis de células |
WO2011025904A1 (en) * | 2009-08-31 | 2011-03-03 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
CA2770351C (en) * | 2009-08-31 | 2019-04-23 | Ibc Pharmaceuticals, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity |
AU2010315432A1 (en) * | 2009-11-05 | 2012-04-12 | Center For Molecular Medicine And Immunology | Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
CA2782398C (en) * | 2009-12-09 | 2017-09-26 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
EP2509629A4 (en) * | 2009-12-09 | 2013-06-26 | Ibc Pharmaceuticals Inc | DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION |
EP2552483A4 (en) * | 2010-04-01 | 2013-09-25 | Immunomedics Inc | USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS |
US9247931B2 (en) | 2010-06-29 | 2016-02-02 | Covidien Lp | Microwave-powered reactor and method for in situ forming implants |
EP2588153A2 (en) | 2010-07-01 | 2013-05-08 | Sofradim Production | Medical device with predefined activated cellular integration |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
AU2011317088B2 (en) * | 2010-10-20 | 2016-01-21 | Eisai, Inc. | Anti-folate receptor alpha antibody glycoforms |
CA2812442A1 (en) * | 2010-11-03 | 2012-05-10 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy |
AU2012258637B2 (en) | 2011-05-24 | 2017-07-20 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
RS56879B1 (sr) * | 2011-08-23 | 2018-04-30 | Roche Glycart Ag | Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija |
HUE039703T2 (hu) * | 2011-08-23 | 2019-01-28 | Roche Glycart Ag | Bispecifikus antigénkötõ molekulák |
EP2747781B1 (en) * | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
CN104363919A (zh) * | 2012-06-01 | 2015-02-18 | Ibc药品公司 | 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物 |
KR102006997B1 (ko) * | 2012-07-03 | 2019-08-02 | 한국생명공학연구원 | IgG Fc 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자 |
EP2885002A4 (en) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
FR3003172B1 (fr) * | 2013-03-15 | 2017-12-08 | Lab Francais Du Fractionnement | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
KR101833602B1 (ko) | 2013-02-26 | 2018-02-28 | 로슈 글리카트 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
CN105451767B (zh) | 2013-03-15 | 2019-10-18 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US9775928B2 (en) | 2013-06-18 | 2017-10-03 | Covidien Lp | Adhesive barbed filament |
CA2924520C (en) | 2013-11-01 | 2023-09-26 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
WO2015102316A1 (ko) * | 2013-12-30 | 2015-07-09 | 경희대학교 산학협력단 | 링커를 통해 연결된 동일한 표적 물질에 결합하는 항체 및 앱타머를 포함하는 집게 분자 및 이의 용도 |
SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
NZ766556A (en) | 2014-08-04 | 2024-02-23 | Hoffmann La Roche | Bispecific t cell activating antigen binding molecules |
CU20170041A7 (es) | 2014-09-26 | 2017-09-06 | Macrogenics Inc | Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3 |
EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
AU2016207112B2 (en) * | 2015-01-16 | 2018-08-02 | Academia Sinica | Molecular constructs with targeting and effector elements |
TWI688572B (zh) | 2015-01-26 | 2020-03-21 | 美商宏觀基因股份有限公司 | 包含dr5-結合結構域的多價分子 |
CN104829730A (zh) * | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
EP3303370A4 (en) | 2015-05-28 | 2019-03-13 | Immunomedics, Inc. | T20 CONSTRUCTION PRODUCTS FOR THERAPY AND / OR ANTI-HIV VACCINES (HUMAN IMMUNODEFICIENCY VIRUS) |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
EP3722318A1 (en) * | 2015-07-06 | 2020-10-14 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
CN108290927B (zh) * | 2015-07-15 | 2022-06-24 | 加州理工学院 | Il-17f-特异性捕获剂、组合物以及使用和制造的方法 |
GEP20227438B (en) | 2015-07-30 | 2022-11-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AU2016329111A1 (en) | 2015-10-02 | 2018-02-08 | F. Hoffmann-La Roche Ag | Bispecific anti-CEAXCD3 T cell activating antigen binding molecules |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
CA2997406A1 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
EP3389714A4 (en) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE |
PL3400246T3 (pl) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3 |
AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
JP7002467B2 (ja) | 2016-04-15 | 2022-01-20 | マクロジェニクス,インコーポレーテッド | 新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法 |
WO2018060301A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies against cd3 |
EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE |
IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific molecules that bind CD137 and cancer antigens and their uses |
KR20190120276A (ko) * | 2017-02-28 | 2019-10-23 | 아피메트 게엠베하 | 항―cd16a 항체와 사이토카인의 조합물 |
GB201705686D0 (en) * | 2017-04-07 | 2017-05-24 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス, インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
IL298402A (en) | 2020-06-19 | 2023-01-01 | Hoffmann La Roche | Antibodies that bind to CD3 and CD19 |
WO2022010798A1 (en) | 2020-07-06 | 2022-01-13 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
CN111848462B (zh) * | 2020-08-14 | 2021-05-11 | 上海大学 | 一种芘磺酸盐衍生物及其制备方法和应用 |
CA3202233A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic BioPharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
CN112553256B (zh) * | 2021-02-20 | 2021-06-22 | 北京百普赛斯生物科技股份有限公司 | Il-2受体复合物及其制备方法与应用 |
CN113533272B (zh) * | 2021-06-26 | 2024-01-09 | 浙江工商大学 | 一种提高时间分辨荧光信号强度的标记方法及应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8501219A (nl) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | Immunologisch complex, de bereiding en toepassing daarvan. |
US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
US20040018587A1 (en) * | 1994-10-13 | 2004-01-29 | Lee Makowski | Nanostructures containing antibody assembly units |
US7060506B2 (en) * | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
US6524854B1 (en) | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
US7432342B2 (en) * | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
US20050003403A1 (en) * | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
EP1874824A4 (en) * | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
-
2006
- 2006-12-05 SG SG200904095-7A patent/SG153825A1/en unknown
- 2006-12-05 KR KR1020087017349A patent/KR101410521B1/ko active IP Right Grant
- 2006-12-05 CN CN200680052809.2A patent/CN101374546B/zh active Active
- 2006-12-05 JP JP2008545643A patent/JP5090366B2/ja active Active
- 2006-12-05 CN CN201310087033.XA patent/CN103242451B/zh active Active
- 2006-12-05 WO PCT/US2006/046367 patent/WO2007075270A2/en active Application Filing
- 2006-12-05 CN CN201610087781.1A patent/CN105709237A/zh active Pending
- 2006-12-05 CA CA2633486A patent/CA2633486C/en active Active
- 2006-12-05 AU AU2006330051A patent/AU2006330051B2/en active Active
- 2006-12-05 EP EP06848816.2A patent/EP1959993B1/en active Active
-
2008
- 2008-09-22 HK HK08110462.0A patent/HK1117761A1/xx unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009519931A5 (ja) | ||
Wei et al. | Clinical development of CAR T cell therapy in China: 2020 update | |
JP2009517337A5 (ja) | ||
Runcie et al. | Bi-specific and tri-specific antibodies-the next big thing in solid tumor therapeutics | |
US20200345854A1 (en) | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof | |
Han et al. | Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy | |
Holzinger et al. | The growing world of CAR T cell trials: a systematic review | |
JP2008538747A5 (ja) | ||
JP2008542194A5 (ja) | ||
JP4212111B2 (ja) | 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体 | |
CA2067244C (en) | Monoclonal antibody specific for iga receptor | |
JP2016520548A5 (ja) | ||
CN111944050A (zh) | 一种抗b7-h3抗体及其应用 | |
Dees et al. | Bispecific antibodies for triple negative breast cancer | |
WO2011130753A2 (en) | Functionalized nano- and micro-materials for medical therapies | |
JP2006514627A5 (ja) | ||
JP2022087135A (ja) | 複数細胞標的化リポソーム | |
Xue et al. | Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy | |
CN108640992A (zh) | 抗人pd1抗体及其应用 | |
WO2019184549A1 (zh) | 双特异性抗体及其应用 | |
RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
Ströhlein et al. | The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis | |
Qiao et al. | LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer | |
Zhao et al. | A promising cancer diagnosis and treatment strategy: Targeted cancer therapy and imaging based on antibody fragment | |
Khorasani et al. | CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges |